Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition
KalVista Pharmaceuticals brings to Chiesi Group the product Ekterly, the first FDA-approved oral drug for acute treatment of swelling attacks from the rare disease hereditary angioedema. Ekterly’s tablet formulation offers a dosing edge compared to injectable HAE medications.
AI-Driven Layoffs In Healthcare: Navigating Legal Risks and Operational Challenges
Layoffs tied to AI adoption will not be uniform; they will vary by sector, job function, and regulatory exposure. Nowhere is this more complex than in healthcare, where legal constraints, patient safety obligations, and labor dynamics intersect with rapid technological change.
Financial Assistance Reform Is Reshaping Revenue Cycle Strategy
Financial assistance is moving from discretionary policy to regulated infrastructure. For health systems, that shift has significant operational and financial implications.
Beyond Support Teams: The Strategic Role of Centers of Excellence in Healthcare
In today’s cash- and staffing-strapped, high-stakes healthcare environment, COEs are an operational necessity. The most successful organizations treat them as long-term strategic investments, or engines for scalable, sustainable transformation.
6 Things to Know About Medtronic’s Cyberattack
Medtronic suffered a cyberattack on its corporate IT systems. The incident highlights growing cybersecurity risks in the medtech sector, with cybergangs increasingly using phishing and other human-engineering tactics to gain access to data.